Hills Bank & Trust Co Boosts Holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Hills Bank & Trust Co increased its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 8.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,239 shares of the biopharmaceutical company’s stock after purchasing an additional 1,004 shares during the period. Hills Bank & Trust Co’s holdings in Alexion Pharmaceuticals were worth $1,401,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. APG Asset Management N.V. increased its position in shares of Alexion Pharmaceuticals by 185.9% during the 1st quarter. APG Asset Management N.V. now owns 132,904 shares of the biopharmaceutical company’s stock valued at $11,933,000 after purchasing an additional 86,412 shares during the last quarter. FDx Advisors Inc. lifted its holdings in shares of Alexion Pharmaceuticals by 52.2% in the 1st quarter. FDx Advisors Inc. now owns 3,055 shares of the biopharmaceutical company’s stock worth $274,000 after buying an additional 1,048 shares during the period. State Street Corp lifted its holdings in shares of Alexion Pharmaceuticals by 1.1% in the 1st quarter. State Street Corp now owns 11,082,433 shares of the biopharmaceutical company’s stock worth $995,092,000 after buying an additional 121,299 shares during the period. State of Alaska Department of Revenue lifted its holdings in shares of Alexion Pharmaceuticals by 40.1% in the 2nd quarter. State of Alaska Department of Revenue now owns 72,286 shares of the biopharmaceutical company’s stock worth $8,112,000 after buying an additional 20,699 shares during the period. Finally, Municipal Employees Retirement System of Michigan lifted its holdings in shares of Alexion Pharmaceuticals by 4.9% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 7,290 shares of the biopharmaceutical company’s stock worth $818,000 after buying an additional 340 shares during the period. 90.12% of the stock is currently owned by institutional investors.

ALXN has been the subject of a number of analyst reports. Morgan Stanley decreased their price objective on Alexion Pharmaceuticals from $121.00 to $119.00 and set an “equal weight” rating for the company in a research note on Friday. SunTrust Banks upped their target price on Alexion Pharmaceuticals from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Friday, July 31st. TheStreet lowered Alexion Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Thursday, July 30th. Raymond James reduced their target price on Alexion Pharmaceuticals from $156.00 to $151.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Finally, BidaskClub raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, September 17th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average target price of $142.43.

Alexion Pharmaceuticals stock traded down $3.67 during midday trading on Friday, hitting $114.54. 38,978 shares of the company were exchanged, compared to its average volume of 2,244,709. The firm has a market capitalization of $25.91 billion, a PE ratio of 30.63, a price-to-earnings-growth ratio of 1.02 and a beta of 1.35. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $72.67 and a fifty-two week high of $128.57. The business has a fifty day simple moving average of $116.67 and a two-hundred day simple moving average of $109.56. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.28 and a current ratio of 4.79.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $3.24 EPS for the quarter, topping the consensus estimate of $2.60 by $0.64. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.43 billion. Alexion Pharmaceuticals had a return on equity of 22.57% and a net margin of 15.28%. Alexion Pharmaceuticals’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same period last year, the company earned $2.79 earnings per share. As a group, equities analysts expect that Alexion Pharmaceuticals, Inc. will post 10.2 earnings per share for the current year.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).

See Also: How does the Beige Book influence monetary policy?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.